Death associated protein kinase 1 predicts the prognosis and the immunotherapy response of various cancers
Molecular Biology Reports · 2024
DOI: 10.1007/s11033-024-09240-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Biology Reports, 2024. Verfasst von Jianjian Yang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei Province, China. Hauptthemen laut MEDLINE: Death-Associated Protein Kinases, Immunotherapy, Biomarkers, Tumor, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Death Associated Protein Kinase 1 (DAPK1) is a calcium/calmodulin-dependent serine/threonine kinase, which has been reported to be a tumor suppressor with unbalanced expression in various tissues. However, its function in tumor immunotherapy is still unclear. METHODS: The online GEPIA2 database was used to support TCGA results. We explored the DAPK1 pan-cancer genomic alteration analysis using the cBioPortal web tool. The Human Protein Atlas (HPA) was employed to mine DAPK1 protein information. We verified the expression of DAPK1 in lung adenocarcinoma samples using RT-qPCR. Subsequently, the relationship between the expression of DAPK1 and the clinical stage was analyzed. We used TIMER2.0 as the primary platform for studying DAPK1-related immune cell infiltration. Associations between DAPK1 and immunotherapy biomarkers were analyzed using Spearman correlation analysis. TMB and MSI expression was also examined. Finally, we used Kaplan-Meier Plots to evaluate the relationship between DAPK1 expression and the efficacy of immunotherapy. RESULTS: DAPK1 is aberrantly expressed in most cancer types and has prognostic power in various cancers. Gene mutation was the most common DAPK1 alteration across pan-cancers. The DAPK1 protein was mainly localized to tumor cell centrosomes. DAPK1 was also significantly associated with immune-activated hallmarks, immune cell infiltration, and the expression of immunomodulators. Notably, DAPK1 can also significantly predict responses to anti-PD1 and anti-CTLA-4 therapy in cancer patients. CONCLUSIONS: Our findings suggest that DAPK1 may not only be an effective prognostic factor in cancer patients but may also function as a promising predictive immunotherapy biomarker for cancer patients treated with immune checkpoint inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei Province, China.
- Department of Anesthesia, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang, 441000, Hubei Province, China.
- Department of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei Province, China. gengqingwhu@whu.edu.cn.
- Department of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei Province, China. rmh_wb@whu.edu.cn.
Zitieren
APA
Yang, J., Liu, Y., Geng, Q., & Wang, B. (2024). Death associated protein kinase 1 predicts the prognosis and the immunotherapy response of various cancers. Molecular Biology Reports. https://doi.org/10.1007/s11033-024-09240-y
Vancouver
Yang J, Liu Y, Geng Q, Wang B. Death associated protein kinase 1 predicts the prognosis and the immunotherapy response of various cancers. Molecular Biology Reports. 2024. doi:10.1007/s11033-024-09240-y
BibTeX
@article{Yang2024,
author = {Yang, Jianjian and Liu, Ying and Geng, Qing and Wang, Bo},
title = {Death associated protein kinase 1 predicts the prognosis and the immunotherapy response of various cancers},
journal = {Molecular Biology Reports},
year = {2024},
doi = {10.1007/s11033-024-09240-y}
}
EUVIMED